No evidence of beneficial effects of plasmapheresis in natalizumab-associated PML.
about
The use of natalizumab for multiple sclerosisNatalizumab granule cell neuronopathy: FDG-PET in diagnosis and immune reconstitution with G-CSF.Neurological safety of fingolimod: An updated reviewNeuro-ophthalmic side effects of molecularly targeted cancer drugs.Biological Agents and Therapeutic Plasma Exchange: Can They Coexist in the Future?To do or not to do? plasma exchange and timing of steroid administration in progressive multifocal leukoencephalopathy.Asymptomatic progressive multifocal leukoencephalopathy: a case report and review of the literature.
P2860
Q33879159-F792A172-1605-4352-B4AA-CE5C93311726Q41048876-64FC0550-34F8-451D-9CF3-72515B879EECQ41553443-22618E5C-B106-44B9-8A06-3424F4AC77D1Q47625145-E91CC898-0AD7-4651-B5AE-654D38431FD3Q47800187-C430A20A-4ACC-4E7C-AA1F-D622871DEEB3Q47812653-D0373957-59D4-45D7-9FB0-8E7BDE895D4AQ55516242-B92A81D0-1713-4C4E-9AED-28437C02D9A7
P2860
No evidence of beneficial effects of plasmapheresis in natalizumab-associated PML.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年論文
@yue
2017年論文
@zh-hant
2017年論文
@zh-hk
2017年論文
@zh-mo
2017年論文
@zh-tw
2017年论文
@wuu
2017年论文
@zh
2017年论文
@zh-cn
name
No evidence of beneficial effects of plasmapheresis in natalizumab-associated PML.
@en
type
label
No evidence of beneficial effects of plasmapheresis in natalizumab-associated PML.
@en
prefLabel
No evidence of beneficial effects of plasmapheresis in natalizumab-associated PML.
@en
P2093
P50
P1433
P1476
No evidence of beneficial effects of plasmapheresis in natalizumab-associated PML
@en
P2093
Doriana Landi
Fabio Buttari
Francesco Mori
Girolama Alessandra Marfia
Italian PML study group
Luca Prosperini
Maria Albanese
Nicola De Rossi
Ruggero Capra
Sara Zagaglia
P304
P356
10.1212/WNL.0000000000003740
P407
P577
2017-02-22T00:00:00Z